BardyDx Appoints President & CEO

Bardy Diagnostics Inc. (BardyDx), a developer and provider of remote ambulatory cardiac monitoring and digital health solutions, has appointed Kevin Hykes as president and chief executive officer, effective August 31, 2020.
 
Hykes will also become a member of BardyDx’s Board of Directors. With over 28 years of experience in the medical device industry, Hykes will be responsible for leading the development and execution of short- and long-term business and financial strategies and managing the overall operations of BardyDx.
 
“I’m very excited and pleased to have Kevin join our executive team as president and CEO. I’ve had the privilege of working with Kevin when he was CEO of the last company I founded, Cameron Health, where he led the global commercialization of the subcutaneous implantable cardioverter defibrillator and ultimately our successful sale to Boston Scientific,” commented Gust H. Bardy, M.D., founder and chairman of BardyDx. “I am looking forward to transitioning into my new role as chief medical officer and chief innovation officer and turning day-to-day management of the company over to Kevin as we continue to experience tremendous growth in the adoption of our CAM p-wave centric patch as the new standard of care in ambulatory cardiac monitoring devices.”
 
Experience
Prior to joining BardyDx, Hykes held operational roles in numerous venture-backed medical device companies including serving as the president and CEO of Relievant Medical Systems, Metavention Inc. and Cameron Health. Hykes has also been an operating partner at both Revival Healthcare Capital and Versant Ventures and currently serves as an independent director at Veran Medical Systems and Metavention Inc. Earlier in his career, Hykes spent sixteen years at Medtronic where he held leadership positions in the CRM, Neurostimulation and Cardiac Surgery business in the United States and Europe.
 
“It’s an honor to join the outstanding team at Bardy Diagnostics and to build upon the significant momentum that the company has established in the marketplace with its best in class ambulatory ECG monitoring and analysis technology,” said Hykes. “The demonstrated clinical superiority of Bardy Diagnostics’ p-wave centric technology uniquely positions the company to capitalize on the growing interest in remote patient monitoring for patients with chronic health conditions.”
 
Warren Watson, a Bardy Diagnostics’ board member, added, “I’ve worked with Kevin at multiple points over the last 20 years and I’m pleased to welcome him to Bardy Diagnostics. Kevin’s extensive experience leading venture-backed medical device companies and his successful track record commercializing breakthrough technologies on a global basis will be instrumental in taking the company to the next level in its growth trajectory.”